

An ESMO-Licensed Event:




#CuUnPas Înainte

BEST OF ESMO Lung Cancer Conference

9-10 May 2025 | Ramada by Wyndham Oradea

Program





9th of May

DAY 1, FRIDAY

10:00 - 12:30

Satellite Symposium by AstraZeneca

Chairman: Șerban Negru

10:00 - 10:05

Introduction

Speaker: Șerban Negru

Targeted therapy in NSCLC EGFRm

10:05 - 10:30

NSCLC EGFRm Adjuvant setting & Clinical Case evidence for adjuvant therapy

Speaker: Răzvan Ovidiu Curcă

10:30 - 10:50

From adjuvant to unresectable stage III in NSCLC EGFRm

Speaker: Mircea Dediu

10:50 - 11:10

mNSCLC EFGR+ landscape: certainties and oportunitites(RWE)

Speaker: Dana Clement

11:10 - 11:30

Enabeling unprecedented patient outcomes across the NSCLC continuum

Speaker: Andrei Ungureanu

Advances of imunotherapy in lung cancer

11:30 - 11:50

IOs role in early stages of NSCLC

Speaker: Aniela Platona

11:50 - 12:10

RWE of IOs role in Stage III NSCLC

Speaker: Daniela Sârbu

12:10 - 12:30

A story of SCLC: from localized to extensive

Speaker: Laura Mazilu





12:30 - 13:20

Lunch Break

13:20 - 13:40

Official Opening - Special Guests

13:40 - 15:20

Academic Session

Chairman: Mircea Dediu

13:40 - 14:10

Moving forward, beyond classical anti PD-1+/- anti CTLA4 suppression, to improve the first line options in non-oncogene driven metastatic NSCLC

Speaker: Răzvan Ovidiu Curcă

14:10 - 14:40

Targeting the resistance mechanism upon first line TKI in EGFR mutant NSCLC

Speaker: Luis Paz-Ares (Madrid, Spain)

14:40 - 15:10

Updates in the treatment of Malignant Mesothelioma

Speaker: Șerban Negru

15:10 - 15:20

Discussion and Q&A



15:20 - 15:40

Coffee Break

15:40 - 17:50

Industry Symposiums

Chairman: Andrei Ungureanu

15:40 - 16:00

SYMPOSIUM BY JHONSON & JHONSON

Transforming clinical practice in EGFR-mutant NSCLC

Speaker: Laura Mazilu

16:00 - 16:15

SYMPOSIUM BY ROCHE

Redefining the standard of care for treatment of ES-SCLC

Speaker: Andrei Ungureanu





16:15 - 17:15

SYMPOSIUM BY ASTRAZENECA

**IMFINZI (Durvalumab) in ES-SCLC: Standard of Care
Supported by Multiple Evidence**

Speaker: Amedeia Niță

**TAGRISO the backbone treatment approach of 1L locally
advanced/metastatic EGFRm NSCLC, continues to
transform patient outcomes**

Speaker: Giuseppe Banna - Portsmouth, UK

17:15 - 17:30

SYMPOSIUM BY PFIZER

**-Optimizing treatment in ALK+ NSCLCa: the role and
importance of Lorlatinib in first line**

Speaker: Andrei Ungureanu

17:30 - 17:45

SYMPOSIUM BY ACCORD

-Efficacy and safety of nab-paclitaxel in lung cancer

Speaker: Vlad Vornicu

17:50 - 18:20

Academic Session

Chairman: Andrei Ungureanu


17:50 - 18:20

**Neoadjuvant, adjuvant or perioperative immunotherapy in
early-stage NSCLC? How to decide!**

Speaker: Laura Mazilu

18:20 - 18:30

Conclusions Day 1





10th of May

DAY 2, SATURDAY

09:00 - 09:10

Opening

Speaker: Mircea Dediu

09:10 - 10:40

Academic Session

Chairs: Mircea Dediu & Andrei Ungureanu

09:10 - 09:40

Immune cell engagers: is it really new or “C'est la même Jeannette autrement coiffée”

Speaker: Giuseppe Banna (Portsmouth, UK)

09:40 - 10:10

KRAS inhibitors in NSCLC: where are we now and where are we heading?

Speaker: Maximilian Hochmair (Vienna, Austria)

10:10 - 10:40

Antibody drug conjugates in NSCLC: are they ready for the Prime

Speaker: Andrei Ungureanu

10:40 - 10:50

Discussions and Q&A



10:50 - 11:10

Coffee Break

11:10 - 12:20

Academic Session

Chairs: Laura Mazilu & Mircea Dediu

11:10 - 12:00

MDT Tumor Board

Panel Experts: Laura Mazilu, Mircea Dediu, Gabriel Kacso, Andrei Lesan, Emanuel Palade, Andrei Ungureanu

1. *Vladimir Preoteasa - NSCLC in Patients with Head and Neck Cancer: Diagnostic and Therapeutic Challenges - A Case Study*

2. *Dana Clement - A multimodal approach for a patient with IIIA (T2N2) NSCLC in the immunotherapy era*





12:00 - 12:30 **Immune therapy in SCLC: what's for sure and what's still challenging?**
Speaker: Bruna Pellini (Florida, USA)

12:30 - 12:50 **Industry Symposium**
Chairman: Mircea Dediu

12:30 - 12:50 **SYMPOSIUM BY REGENERON | MEDISON**
Libtayo - first line treatment in NSCLC locally advanced and metastatic
Speaker: Andrei Ungureanu

12:50 - 13:00 **Discussions and Q&A**



13:00 - 14:00 **Lunch Break**

14:00 - 15:30 **Academic Session**
Chairman: Diana Ionescu

14:00 - 14:30 **Pollution and lung carcinogenesis: what are the supportive data?**
Speaker: Gabriel Gati

14:30 - 15:00 **Past, present and future in the SCLC treatment**
Speaker: Lucian Miron

15:00 - 15:10 **Discussions and Q&A**

15:10 - 15:40 **Pathology clues in defining various neuroendocrine lung cancer tumors**
Speaker: Diana Ionescu

15:40 - 15:50 **Discussions and Q&A**





15:50 - 16:35

Industry Symposium

Chairman: Mircea Dediu

15:50 - 16:35

SYMPOSIUM BY BMS

**CheckMate 9LA Translating clinical data into medical practice
-RWD FINN**

Speaker: Andrei Ungureanu

**Is it time for a new treatment approach in non-metastatic,
resectable NSCLC ?**

Speaker: Mircea Dediu



16:35 - 17:00

Coffee Break

17:00 - 17:45

Industry Symposium

Chairman: Laura Mazilu

17:00 - 17:30

SYMPOSIUM BY MSD

**Multidisciplinary approach in the treatment of the Patient
with bronchopulmonary Cancer: A necessity in Clinical
Practice**

Speaker: Tudor Ciuleanu, Bogdan Popovici

17:30 - 17:45

SYMPOSIUM BY TAKEDA

NSCLC ALK+: Updates in the recent literature

Speaker: Tudor Ciuleanu

17:45 - 18:45

Interactive Debate Session

TKI single agent vs Combinations in first line EGFR

Speakers:

Tudor Ciuleanu in favour of single agent

Mircea Dediu in favour of combinations

18:45 - 19:00

Final discussion and conclusions

